Stephen J. Denelsky, Director at HARVARD BIOSCIENCE INC (HBIO), bought 10,000 shares at $4.87 ($49K) on 2026-03-17, disclosed to the SEC on 2026-03-18.
Director Stephen J. Denelsky purchased 10,000 shares at $4.87 on March 17, 2026, marking the largest insider purchase in the company's history. This significant accumulation comes as the stock trades near a 52-week low, potentially signaling confidence in the company's turnaround.
HBIO is currently trading at $4.88, down 36.39% over the last 90 days and sitting 48.4% below its 52-week high of $9.46. The stock has recovered 73.48% from its 52-week low of $2.81, suggesting a volatile but potentially oversold setup.
Q1 2026 earnings call on May 12, 2026, expected to discuss revenue growth from new product lines; manufacturing relocation to Holliston, MA, announced on February 3, 2026, to generate $4 million in annual cost savings.
Analysts recently cut the fair value estimate from $2.00 to $0.60 on March 16, 2026, citing lower 2026 revenue expectations of $89.2m. Additionally, the stock carries a short interest of 3.85% of the float, which could exacerbate volatility if the insider purchase fails to spark a rebound.
Something here stands out, but not much.